Check 35,000+ stocks against 26 valuation models and 37 quality factors

BioInvent International AB (BINV) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of BioInvent International AB SEK 7.96, price SEK 20.80, upside -61.7%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · SE · ISIN SE0015244520

Thin data Sep 24, 2026

BioInvent International AB

BINV · ST

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 7.96 · Strongly overvalued (−62%)

!Quality 50/100

!Weak Growth (revenue 5y +9.0 %/yr)

!Loss-making · -154.0% net margin (TTM)

!negative free cash flow

!Mixed vs. peers (4/9)

!Narrow moat 12/100

!Insider activity 40/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear kr 5.26 to bull kr 9.96 Growth analysisrevenue history, year by year Quality 50/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch BioInvent International AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range kr 14.14 – kr 57.55 · fair‑value band kr 5.26 – kr 9.96 · the kr 20.80 price screens above the kr 7.96 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow BioInvent International in your weekly email

Every Wednesday you see whether BioInvent International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally.

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.

Stock analysis

BioInvent International AB (BINV) currently trades at kr 20.80, while our model-based Fair Value estimate is kr 7.96, implying the stock looks roughly 161.3% overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: kr 5.26 (bear) to kr 9.96 (bull), the price of kr 20.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

BioInvent International AB reported revenue of 226M SEK in FY2025 versus 19.4M SEK in FY2021, a compound +84.9%/yr. Reported net income was −333M SEK in FY2025.

Key figures

Market cap 1.5B SEK (≈ $149M) · P/S ratio 6.80 · EPS (TTM) kr −5.10 · Net margin −147% · Return on equity −55.5% · Return on assets (EBIT) −29.7% · Operating margin −907% · Revenue (TTM) 218M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 39% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −62%, BINV screens richer than that median.

Fair Value models

Bear kr 5.26 Fair Value kr 7.96 Bull kr 9.96

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) kr 4.24 kr 5.68 kr 8.47 51

All 1 models by family

Asset-Based

NCAV (Graham) kr 4.24 kr 5.68 kr 8.47 51

Open the full fair value analysis →

Notify me when BINV reaches fair value

Put BINV on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 50/100

Of which business quality 50 · Market factors (momentum, volatility) 27

Profitability 16

Margins and returns on capital today

Quality Growth 70

Are margins and returns improving?

Cashflow 5

Earnings quality: real cash, not paper profit

Fin. Strength 75

Balance sheet, leverage, solvency risk

Investment 98

Disciplined investing over empire-building

Low Volatility 57

Calm price path (market factor)

Momentum 23

Price trend over the last 3–12 months (market factor)

52W Momentum 0

Distance to the 52-week high (market factor)

Net Issuance 70

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+406.9%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−11.4%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.0%

Start year 2020 (pandemic)

Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.4%

’12

’13

’14

’16

’17

’18

’19

’20

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−51.2% (2020) → −155.1% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

BINV screens 161% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare BioInvent International AB with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks

Beats the industry median on 4/8 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 50 · Above median

Fair Value upside −64% · Below median

Profitability

Return on assets −31% · Bottom 25%

Net margin (TTM) −154% · Bottom 25%

Growth and dividend

Revenue growth −39% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.26× · Cheapest 25%

P/S (TTM) 0.68× · Cheapest 25%

PEG 0.27× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$514.99	$566.49	+10%
Regeneron Pharmaceuticals, Inc REGN	$803.90	$1,252	+56%
argenx SE ARGX	$963.79	$918.60	−5%
Samsung Biologics Co 207940	1,366,000 KRW	1,502,600 KRW	+10%
CSL Limited CSL	A$179.24	A$197.16	+10%
Alnylam Pharmaceuticals, Inc ALNY	$251.65	$218.36	−13%
Royalty Pharma plc RPRX	$58.52	$24.22	−59%
BeOne Medicines AG 6160	HK$218.20	HK$169.72	−22%
Celltrion, Inc 068270	177,400 KRW	74,519 KRW	−58%
BioNTech SE BNTX	$100.87	$63.62	−37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BioInvent International AB · Fair Value
kr 7.96 −161%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/BINV" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">BioInvent International AB · Fair Value</span><br><b style="font-size:20px">kr 7.96</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−161%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "BioInvent International AB Fair Value". https://www.fairvalue-calculator.com/stock/BINV

Frequently asked questions

Is BioInvent International AB (BINV) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of kr 7.96 versus a price of kr 20.80, about −62% upside (overvalued).

What is the fair value of BINV?

Our model-based fair value for BioInvent International AB is kr 7.96 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 20.80.

What is the quality score of BINV?

BioInvent International AB has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for BioInvent International AB (BINV)?

Our model-based price target is the fair value of kr 7.96 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 5.26, optimistic scenario kr 9.96. It is a calculation from audited fundamentals, not an analyst target.

What is the BioInvent International AB stock forecast for 2026?

Our models put fair value at kr 7.96, about −62% upside versus a price of kr 20.80 (overvalued). Cautious scenario kr 5.26, optimistic scenario kr 9.96. The calculation is refreshed regularly with new filings.

What is the revenue of BioInvent International AB (BINV)?

BioInvent International AB reported trailing-twelve-month revenue of about 218M SEK (latest available figure, as of Sep 24, 2026).

What is the intrinsic value of BioInvent International AB (BINV)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioInvent International AB it is kr 7.96 per share (as of Sep 24, 2026), against a price of kr 20.80. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is BioInvent International AB stock overvalued or undervalued in 2026?

As of Sep 24, 2026, BINV trades above its calculated fair value: price kr 20.80, fair value kr 7.96, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of BINV?

No. The price is what the market pays today (kr 20.80); the fair value is what the company's own numbers justify (kr 7.96). For BioInvent International AB the two are kr 12.84 per share apart. That gap is exactly why we show both numbers side by side.

How much is BioInvent International AB worth?

The market values BioInvent International AB at about 1.5B SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 20.80; our models calculate a fair value of kr 7.96 per share.

What do the bullish and bearish scenarios say about BINV?

Our models span a range for BioInvent International AB: cautious scenario kr 5.26, base kr 7.96, optimistic kr 9.96 per share (as of Sep 24, 2026, price kr 20.80). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the PEG ratio of BINV?

The PEG ratio of BioInvent International AB is 0.27 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.

How solid is the balance sheet of BioInvent International AB (BINV)?

Balance-sheet figures for BioInvent International AB (as of Sep 24, 2026): return on equity −55.5%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.

How far is BINV from its 52-week high?

BioInvent International AB trades at kr 20.80, about 39% below its 52-week high of kr 33.90 and at the low of kr 20.80 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 7.96 is for.

Which stocks are comparable to BioInvent International AB?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is BioInvent International AB stock attractive at the current price?

The data as of Sep 24, 2026: price kr 20.80, calculated fair value kr 7.96 (−62%), Quality Score 50/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of BINV calculated?

We run BioInvent International AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 7.96, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.2 % above its aggregate fair value. BioInvent International AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of BioInvent International AB (BINV)?

The closing price on Sep 24, 2026 was kr 20.80. Our model-based fair value is kr 7.96, about −62% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with BioInvent International AB right now?

The price sits above even our optimistic bull case (kr 9.96). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 5.26 to kr 9.96) leaves room in how you read the outcome.

Key figures of BioInvent International AB

How large is the market capitalisation of BioInvent International AB (BINV)?

The market capitalisation of BioInvent International AB is 1.5B SEK (≈ $149M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of BioInvent International AB (BINV)?

The price-to-sales ratio of BioInvent International AB is 6.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of BioInvent International AB (BINV)?

Earnings per share at BioInvent International AB are kr −5.10. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of BioInvent International AB (BINV)?

The net margin of BioInvent International AB is −147% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of BioInvent International AB (BINV)?

The return on equity (ROE) of BioInvent International AB is −55.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of BioInvent International AB (BINV)?

On an EBIT basis the return on assets of BioInvent International AB is −29.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of BioInvent International AB (BINV)?

The operating margin of BioInvent International AB is −907% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at BioInvent International AB (BINV)?

Revenue at BioInvent International AB is growing −39.2% versus a year earlier (3y avg −11.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does BioInvent International AB (BINV) generate?

The free cash flow of BioInvent International AB is −255M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does BioInvent International AB (BINV) hold?

BioInvent International AB holds more cash than debt, 346M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch BioInvent International AB in the live analysis

One click puts BioInvent International AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.